Literature DB >> 19034031

Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.

Nicholas B Norgard1, S Saya, C L Hann, T A Hennebry, E Schechter, G L Dale.   

Abstract

INTRODUCTION: Coated-platelets are a subclass of highly thrombotic activated platelets with an enhanced ability to generate thrombin. Excessive numbers of coated-platelets are believed to increase thrombotic risk. A previous report demonstrated that P2Y12 inhibition in vitro attenuates coated-platelet formation. The aim of this study was to determine the effect clopidogrel has on coated-platelet formation. METHODS AND
RESULTS: We enrolled 27 patients undergoing elective coronary angiography. A total of 3 blood samples were taken from eligible patients: baseline, 24-hour postclopidogrel (preangiography), and 6-hour postangiography. Coated-platelet levels, expressed as percentage of total platelets, were determined with convulxin and thrombin with or without 1.5 or 6 microM adenosine diphosphate (ADP). Baseline levels of coated-platelets were 40.0% +/- 14.3% (mean +/- 1 SD). After clopidogrel exposure, the coated-platelet level was 32.8% +/- 13.6%, representing a significant 7.2% absolute reduction (AR) (17.8% relative reduction (RR); P < 0.0001). Clopidogrel significantly lowered the convulxin, thrombin plus ADP coated-platelet production (11.0% AR; 20.1% RR for 1.5 microM and 11.2% AR; 19.1% RR for 6 microM).
CONCLUSIONS: This is the first report on the impact of in vivo administration of a P2Y12 antagonist on coated-platelet formation. The significance of a partial attenuation in coated-platelet potential has yet to be determined, but this could represent a new antithrombotic mechanism of clopidogrel beyond inhibition of ADP-induced aggregation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034031     DOI: 10.1097/FJC.0b013e3181907390

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction.

Authors:  Calin I Prodan; Julie A Stoner; Linda D Cowan; George L Dale
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-14       Impact factor: 6.200

2.  Necrotic platelets provide a procoagulant surface during thrombosis.

Authors:  Vu Minh Hua; Latasha Abeynaike; Elias Glaros; Heather Campbell; Leonardo Pasalic; Philip J Hogg; Vivien M Y Chen
Journal:  Blood       Date:  2015-10-16       Impact factor: 22.113

3.  Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Authors:  Fabiana Rollini; Francesco Franchi; Jung Rae Cho; Christopher Degroat; Mona Bhatti; Elisabetta Ferrante; Ronakkumar Patel; Andrew Darlington; Antonio Tello-Montoliu; Bhaloo Desai; Joséluis Ferreiro; Ana Muniz-Lozano; Martin M Zenni; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2014-01-07       Impact factor: 4.132

4.  Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease.

Authors:  C I Prodan; E D Ross; J A Stoner; L D Cowan; A S Vincent; G L Dale
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

5.  Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response.

Authors:  L Pasalic; E Wing-Lun; J K Lau; H Campbell; G J Pennings; E Lau; D Connor; H P Liang; D Muller; L Kritharides; P J Hogg; V M Chen
Journal:  J Thromb Haemost       Date:  2018-05-08       Impact factor: 5.824

Review 6.  Mechanisms Underlying Dichotomous Procoagulant COAT Platelet Generation-A Conceptual Review Summarizing Current Knowledge.

Authors:  Lucas Veuthey; Alessandro Aliotta; Debora Bertaggia Calderara; Cindy Pereira Portela; Lorenzo Alberio
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

7.  Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.

Authors:  Christine S M Lee; Maria V Selvadurai; Leonardo Pasalic; James Yeung; Maria Konda; Geoffrey W Kershaw; Emmanuel J Favaloro; Vivien M Chen
Journal:  J Thromb Haemost       Date:  2022-02-07       Impact factor: 16.036

Review 8.  P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.

Authors:  Alexandre Mansour; Christilla Bachelot-Loza; Nicolas Nesseler; Pascale Gaussem; Isabelle Gouin-Thibault
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.